NeuroBo Pharmaceuticals Files 8-K Report
Ticker: MTVA · Form: 8-K · Filed: Mar 13, 2024 · CIK: 1638287
| Field | Detail |
|---|---|
| Company | Neurobo Pharmaceuticals, INC. (MTVA) |
| Form Type | 8-K |
| Filed Date | Mar 13, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-reporting, exhibits
TL;DR
NeuroBo Pharma filed an 8-K on March 13, 2024, mostly about financials and exhibits.
AI Summary
On March 13, 2024, NeuroBo Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating ongoing operational and reporting activities for the company, which is involved in pharmaceutical preparations.
Why It Matters
This filing provides an update on NeuroBo Pharmaceuticals' financial and exhibit information, which is crucial for investors and stakeholders to assess the company's current status and compliance.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, not indicating any immediate significant operational or financial distress.
Key Numbers
- 001-37809 — SEC File Number (Identifies the company's filing with the SEC.)
- 47-2389984 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- NeuroBo Pharmaceuticals, Inc. (company) — Registrant
- March 13, 2024 (date) — Date of Report
- Gemphire Therapeutics Inc. (company) — Former Company Name
- 545 Concord Avenue, Suite 210, Cambridge, Massachusetts 02138 (location) — Business Address
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' as of March 13, 2024.
What was NeuroBo Pharmaceuticals' former company name?
NeuroBo Pharmaceuticals, Inc.'s former company name was Gemphire Therapeutics Inc., with a date of name change on March 31, 2015.
Where is NeuroBo Pharmaceuticals, Inc. headquartered?
NeuroBo Pharmaceuticals, Inc.'s principal executive offices are located at 545 Concord Avenue, Suite 210, Cambridge, Massachusetts 02138.
What is the SEC file number for NeuroBo Pharmaceuticals?
The SEC file number for NeuroBo Pharmaceuticals, Inc. is 001-37809.
When was the earliest event reported in this filing?
The earliest event reported in this filing is dated March 13, 2024.
Filing Stats: 554 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2024-03-13 08:30:25
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share NRBO The Nasdaq Stock Mar
Filing Documents
- nrbo-20240313x8k.htm (8-K) — 42KB
- nrbo-20240313xex99d1.htm (EX-99.1) — 18KB
- nrbo-20240313x8k001.jpg (GRAPHIC) — 12KB
- nrbo-20240313xex99d1001.jpg (GRAPHIC) — 13KB
- 0001558370-24-003055.txt ( ) — 231KB
- nrbo-20240313.xsd (EX-101.SCH) — 3KB
- nrbo-20240313_lab.xml (EX-101.LAB) — 15KB
- nrbo-20240313_pre.xml (EX-101.PRE) — 9KB
- nrbo-20240313x8k_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On March 13, 2024, NeuroBo Pharmaceuticals, Inc. (the "Company" ) issued a press release announcing that the Company received Safety Review Committee (SRC) approval, recommending that the two-part Phase 2a trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), continue without modification following a blinded safety review of the first six months of study conduct. The Phase 2a clinical trial is designed to evaluate the efficacy and safety of DA-1241, for the treatment of MASH. The company anticipates a full data readout from the trial in the second half of 2024. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Information contained on or accessible through any website reference in the press release is not part of, or incorporated by reference in, this Current Report on Form 8-K, and the inclusion of such website addresses in this Current Report on Form 8-K by incorporation by reference of the press release is as inactive textual references only.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press Release dated March 13, 2024. 104 Cover Page Interactive Data File (embedded within Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUROBO PHARMACEUTICALS, INC. Date: March 13, 2024 By: /s/ Hyung Heon Kim Hyung Heon Kim President and Chief Executive Officer